Cardiomyopathy, Dilated Clinical Trial
Official title:
Pilot Study of Immunoadsorption Therapy for Patients With Chronic Non-Ischemic Dilated Cardiomyopathy
The purpose of this study is to evaluate the clinical safety and feasibility of Mysorba in patients with chronic non-ischemic dilated cardiomyopathy (DCM).
Status | Terminated |
Enrollment | 2 |
Est. completion date | June 2012 |
Est. primary completion date | June 2012 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. Subject is 18 years of age or older. 2. Subject has provided written informed consent. 3. Subject has been classified as NYHA Class II or III. 4. Subject has been diagnosed with chronic non-ischemic dilated cardiomyopathy, defined as left ventricular ejection fraction (LVEF) < 40% and left ventricular end diastolic dimensions (LVEDd) > 55 millimeters (mm) or LVEDd/BSA > 3.0 cm/m2. 5. Subject was diagnosed with non-ischemic dilated cardiomyopathy = 6 months and = 5 years prior to screening visit. 6. Subject is on stable optimal medical therapy, consisting of ACE inhibitor (or ARB), ß-blocker, and diuretic, for heart failure for at least 3 months 7. Subject and physician agree to switch subject from ACE inhibitors to ARB for the treatment duration. Exclusion Criteria: 1. Subject has been classified as NYHA Class I or IV 2. Subject is currently pregnant, lactating, or of child-bearing potential and not taking adequate birth control as assessed by Investigator. 3. Subject is HBV, HCV or HIV positive. 4. Subject has anemia, defined as hemoglobin < 10.0 g/dL. 5. Subject has compromised renal function as reflected by a serum creatinine level >3.0 mg/dL or eGFR <30 mL/min or is currently on dialysis. 6. Subject has compromised hepatic function as measured by SGPT (ALT) or SGOT (AST) > three (3) times the upper limit of normal. 7. Subject had acute myocarditis = 3 months prior to screening visit. 8. Subject has a history of diameter stenosis >70% of at least one major coronary artery, as determined by angiography or CTA obtained within the previous 5 years. 9. Subject is on immunosuppressive or immunomodulation therapy: intravenous (IV), intramuscular (IM), or oral. 10. Subject has a history of the following pre-existing heart disease: - myocardial infarction (MI), percutaneous coronary intervention (PCI), or coronary artery bypass graft (CABG) - valvular heart disease requiring repair, replacement, or balloon valvuloplasty - hypertrophic/restrictive cardiomyopathy or constrictive pericarditis 11. Subject is currently participating in, or = 6 months prior to screening visit has participated in, an investigational study of a new drug, biologic, or device. 12. Subject has left ventricular noncompaction. 13. Subject has a left ventricular assist device (LVAD). 14. Subject has received a heart transplant. 15. Subject has DCM due to any of the following: - amyloidosis - sarcoidosis - connective tissue disease - peripartum cardiomyopathy - alcoholism - endocrine dysfunction as the primary cause of DCM - prior illicit drug use which the investigator feels as likely cause for the cardiomyopathy - hereditary and familial conditions (such as genetic dilated cardiomyopathy, familial storage disease, Heredofamilial neurologic and neuromuscular diseases) 16. Subject has undergone cardiac resynchronization therapy = 6 months prior to screening visit. 17. Subject is unable to take ARB in place of ACE inhibitors. 18. Subject has a history of stroke = 3 months prior to screening visit. 19. Subject currently has severe systemic infection requiring treatment with antibiotics. 20. Subject currently has hemodynamic instability defined as systolic blood pressure < 90 mm Hg without afterload reduction, or cardiogenic shock, or the need for inotropic support or intra-aortic balloon pump. 21. Subject has previously undergone immunosuppressive or immunomodulation therapy. 22. Subject has known hypersensitivity or contraindication to heparin including history of heparin induced thrombocytopenia (HIT). 23. Subject has history of drug or alcohol abuse or is currently abusing alcohol or drugs. 24. Subject has active malignancy or tumor, or other non-cardiac medical condition, which causes life expectancy to be less than one year. 25. History of neutropenia (WBC < 3,000/mm3), coagulopathy, or thrombocytopenia (platelet count < 100,000/µL) that has not resolved or has required treatment in the past 6 months. 26. Subject weighs less than 40 kg (88 lbs). 27. Subject requires major elective procedures (AHA-defined intermediate to high risk surgery) within 6 months post-treatment. |
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Cleveland Clinic | Cleveland | Ohio |
United States | Mayo Clinic | Rochester | Minnesota |
Lead Sponsor | Collaborator |
---|---|
Asahi Kasei Medical Co., Ltd. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Rate of Procedure Related Serious Adverse Events (SAE) at 30 Days Post-treatment. | 30 Days Post Treatment | Yes | |
Primary | Rate of Device Related Serious Adverse Events (SAE) at 30 Days Post-treatment. | 30 days post-treatment | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03560167 -
Early Feasibility Study of the AccuCinch® Ventricular Restoration System in Patients With Prior Mitral Valve Intervention (PMVI) and Recurrent Mitral Regurgitation
|
N/A | |
Terminated |
NCT00624520 -
Mental Stress Reduction in Defibrillator Patients
|
Phase 3 | |
Completed |
NCT00549861 -
Characterization of Irreversible Myocardial Injury in Cardiomyopathies by Contrast-enhanced CMR
|
N/A | |
Terminated |
NCT04222101 -
Association of Insulin Resistance and FGF21 on Cardiac Function in Pediatric Dilated Cardiomyopathy
|
N/A | |
Not yet recruiting |
NCT02517814 -
Vitamin D Supplementation Can Improve Heart Function in Idiopathic Cardiomyopathy
|
N/A | |
Completed |
NCT01940081 -
The Leiden Nonischemic Cardiomyopathy Study
|
||
Completed |
NCT01391507 -
Pilot Study of COR-1 in Heart Failure
|
Phase 2 | |
Completed |
NCT01181414 -
Spanish Atrial Fibrillation And Resynchronization Study
|
Phase 4 | |
Not yet recruiting |
NCT06091475 -
Therapy to Maintain Remission in Dilated Cardiomyopathy
|
N/A | |
Recruiting |
NCT03340675 -
Oral Ifetroban in Subjects With Duchenne Muscular Dystrophy
|
Phase 2 | |
Recruiting |
NCT05981092 -
A Study About the Natural History in Adults With BAG3 Dilated Cardiomyopathy (a Type of Heart Disease)
|
||
Not yet recruiting |
NCT06039072 -
Clinical Observation of Long-term Cardiac Function Prognosis in Patients With PPCM Who Have Recovered Cardiac Function
|
||
Recruiting |
NCT03910725 -
Electrophysiological Phenotyping Of Patients at Risk of Ventricular Arrhythmia and Sudden Cardiac Death
|
||
Recruiting |
NCT00221780 -
Role of Left Ventricular Pacing Site
|
N/A | |
Terminated |
NCT02958098 -
My Research Legacy Pilot Study
|
||
Completed |
NCT00123071 -
Variability of Ventricular Mass, Volume, & Ejection Fraction in Pediatric Cardiomyopathy Patients-Pediatric Heart Network
|
N/A | |
Completed |
NCT00284713 -
Progenitor Cell Therapy in Dilative Cardiomyopathy
|
Phase 1/Phase 2 | |
Completed |
NCT01260402 -
Randomized Comparison of Endocardial Versus Epicardial - From the Coronary Sinus - Left Ventricular Pacing for Resynchronization in Heart Failure.
|
N/A | |
Completed |
NCT04192214 -
The Persistence of Autoantibody Neutralisation by BC 007 in Patients With Chronic HFrEF and Autoantibodies Against the Beta1-Adrenergic Receptor
|
Phase 2 | |
Recruiting |
NCT03040947 -
MRI Sequence and Imaging Protocol Development
|